Arterra Bioscience

Milan Stock Exchange ARBS.MI

Arterra Bioscience EBITDA Margin for the year ending December 31, 2023: 55.29%

Arterra Bioscience EBITDA Margin is 55.29% for the year ending December 31, 2023, a -7.62% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Arterra Bioscience EBITDA Margin for the year ending December 31, 2022 was 59.84%, a 29.58% change year over year.
  • Arterra Bioscience EBITDA Margin for the year ending December 31, 2021 was 46.18%, a -18.65% change year over year.
  • Arterra Bioscience EBITDA Margin for the year ending December 31, 2020 was 56.77%, a 24.44% change year over year.
  • Arterra Bioscience EBITDA Margin for the year ending December 31, 2019 was 45.62%, a 82.12% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
Milan Stock Exchange: ARBS.MI

Arterra Bioscience

CEO Ms. Maria Gabriella Colucci
IPO Date Oct. 28, 2019
Location Italy
Headquarters via Benedetto Brin, 69 Napoli, 80142Italy
Employees 34
Sector Healthcare
Industries
Biotechnology Biofuel Bread & Bakery Chemicals & Advanced Materials Cosmetics Personal Care Pharmaceuticals Plastics
Description

Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. Arterra Bioscience S.p.A. was founded in 2003 and is based in Naples, Italy.

StockViz Staff

February 7, 2025

Any question? Send us an email